suprefact injectable 1 mg/ml
sanofi-aventis singapore pte. ltd. - buserelin acetate eqv buserelin - injection - 1 mg/ml
suprefact buserelin acetate 1.05 mg/ml solution for injection vial
sanofi-aventis australia pty ltd - buserelin acetate -
suprefact depot 3 months
sanofi-aventis ireland limited - buserelin acetate - implant - 9.9 milligram
suprefact 100 nasal spray
sanofi-aventis new zealand limited - buserelin acetate 1 mg/ml - nasal spray solution - 1 mg/ml - active: buserelin acetate 1 mg/ml
suprefact depot
sanofi-aventis new zealand limited - buserelin acetate 6.6mg equivalent to 6.3 mg of buserelin - subcutaneous implant - 6.3 mg - active: buserelin acetate 6.6mg equivalent to 6.3 mg of buserelin excipient: polyglactin
suprefact depot
sanofi-aventis new zealand limited - buserelin acetate 9.9mg equivalent to 9.45 mg of buserelin - subcutaneous implant - 9.45 mg - active: buserelin acetate 9.9mg equivalent to 9.45 mg of buserelin excipient: polyglactin
suprefact depot 2 months
sanofi - aventis israel ltd - buserelin acetate 6.6 mg - rods for implant - buserelin - treatment of advanced hormone - dependent prostatic carcinoma.
suprefact nasal spray
sanofi - aventis israel ltd - buserelin as acetate 0.1 mg/actuations - solution - buserelin - treatment of advanced hormone dependent prostatic carcinoma. endometriosis. use in ivf. precocious puberty. leyomyoma uteri.
suprefact nasal spray 0.1 mg
yousif mahmood hussain pharmacy - buserelin acetate - nasal spray - 0.1